News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DiaKine Therapeutics, Inc. Drug Improves Type 2 Insulin Action; Reduces Harm of Fat in Preclinical Study


1/22/2009 9:11:35 AM

BANFF, Alberta--(BUSINESS WIRE)--Results of a preclinical study involving DiaKine Therapeutics’ lead drug candidate Lisofylline (LSF) indicate the compound may reduce two key risk factors for type 2 diabetes.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES